REYON Pharmaceutical Co., Ltd. (KRX:102460)

Market Cap	197.72B
Revenue (ttm)	149.34B
Net Income (ttm)	-14.25B
Shares Out	18.34M
EPS (ttm)	-773.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,515
Average Volume	31,846
Open	10,780
Previous Close	10,780
Day's Range	10,700 - 10,850
52-Week Range	9,830 - 14,430
Beta	0.54
RSI	40.10
Earnings Date	Feb 13, 2026

About REYON Pharmaceutical

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1955
• Employees: 440
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 102460

Financial Performance

In 2024, REYON Pharmaceutical's revenue was 148.30 billion, a decrease of -1.83% compared to the previous year's 151.07 billion. Earnings were 4.15 billion, an increase of 15.85%.